APGE vs JPM · $2.34B cap vs P/E 14, rev $57.35B
Apogee Therapeutics, Inc. Common Stock (APGE) versus JPMorgan Chase & Co (JPM) — a side-by-side from cached financials, not a winner call.
Apogee Therapeutics, Inc. Common Stock (APGE) is a biotechnology company listed on US.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
APGE does not have a complete income-statement cache yet.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
APGE currently screens at market cap $2.34B. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Not investment advice. Open the APGE and JPM stock pages for the full models.
Not investment advice.